The disease activity of mycobacterial infections is typically assessed based on sputum culture results and other indicators. However, these assessments often lack objectivity and quantitative precision. Therefore, there is a need for biomarkers that can objectively and quantitatively evaluate disease activity and aid in determining treatment strategies. We are currently investigating potential substances that could serve as biomarkers for disease activity using clinical samples.
*Corresponding Author
Return to the List of Research Themes
Return to the List of Commitment to Research